Binary combination effects of some pharmacologically active chemicals as promoters of tumorigenesis

V R Rao1

  • 1Science Applications International Corporation, McLean, VA 22102.

Insights

Assessing combined exposures to carcinogens and cancer-promoting pharmaceuticals is challenging. Research identified pharmaceuticals as a class of compounds that can interact with carcinogens, influencing cancer risk.

Area of Science:

  • Toxicology
  • Pharmacology
  • Carcinogenesis

Background:

  • Assessing combined exposures to carcinogens and cancer-modifying agents is complex for human health risk evaluations.
  • Numerous pharmacologically active agents have demonstrated tumor-promoting capabilities in experimental carcinogenesis studies over the last 40 years.

Purpose of the Study:

  • To investigate the chemical structural basis for interactions between binary combinations of carcinogenic chemicals and carcinogenesis-modifying agents.
  • To identify and discuss chemical class-class interactions between carcinogens and pharmaceutical agents with known tumor-promoting properties.

Main Methods:

  • Review of experimental carcinogenesis studies.
  • Analysis of chemical structures and pharmacological activities of tumorigenesis promoters.
  • Discussion of potential biochemical mechanisms underlying interactions.

Main Results:

  • Identification of pharmaceuticals as a class of structurally diverse, pharmacologically active tumorigenesis promoters.
  • Established that pharmaceuticals can interact with carcinogenic chemicals.

Conclusions:

  • Pharmaceuticals represent a significant class of compounds involved in chemical interactions that modify carcinogenesis.
  • Understanding these interactions is crucial for accurate human health risk assessment.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Effects of Chemicals: Overview01:27

Effects of Chemicals: Overview

Drugs, encompassing various chemical compounds from natural sources, lab synthesis, or genetic engineering, elicit different biological responses in living organisms. Some of these responses are desirable or therapeutic, while others are undesirable. The primary goal of administering a drug is to achieve a therapeutic effect, that is, to address a specific disease or health condition. Any concurrent effects outside of this therapeutic outcome are considered undesirable. These undesirable...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...